We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Avalo Therapeutics Inc (AVTX) USD0.001

Sell:$2.16 Buy:$2.17 Change: $0.0013 (0.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0013 (0.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0013 (0.06%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avalo Therapeutics, Inc., formerly Cerecor, Inc., is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes targeted therapeutics for patients with clinical need in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates include AVTX-002, AVTX-007, AVTX-006 and AVTX 800 programs. Its AVTX-002 is an Anti-LIGHT mAb targeting immune-inflammatory diseases including acute respiratory distress syndrome (ARDS) and moderate-to-severe inflammatory bowel disease. Its AVTX-007 is an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases including multiple myeloma and Still’s disease. Its AVTX-006 is a dual mTORc1/c2 inhibitor targeting lymphatic malformations. Its AVTX 800 programs include AVTX-801, AVTX-802 and AVTX-803. Its AVTX 800 programs is a therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).

Contact details

540 Gaither Rd Ste 400
United States
+1 (410) 5228707

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$247.11 million
Shares in issue:
110.32 million
United States
US dollar

Key personnel

  • Michael Cola
    Chairman of the Board, Chief Executive Officer
  • Schond Greenway
    Chief Financial Officer, Principal Financial Officer, Treasurer
  • Christopher Sullivan
    Chief Accounting Officer, Principal Accounting Officer
  • Garry Neil
    Chief Scientific Officer
  • Jamie Harrell
    Chief Commercial Officer
  • H. Jeffrey Wilkins
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.